Pretreatment metabolic tumor volumes to predict the short-term outcome of unresectable locally advanced squamous cell carcinoma of the esophagus treated with definitive chemoradiotherapy.
aDepartment of Radiation Oncology bGraduate Institute of Clinical Medicine Science and School of Medicine, College of Medicine cDepartment of Nuclear Medicine and PET Center dDepartment of Biomedical Imaging and Radiological Science eDivision of Hematology and Oncology, China Medical University Hospital, Taichung fSchool of Medicine, Taipei Medical University, Taipei gDepartment of Medical Imaging and Radiological Sciences, I-Shou University, Kaohsiung, Taiwan.
- Published Article
Nuclear medicine communications
- Publication Date
Mar 01, 2014
Pretreatment MTV20% is a novel marker for OS and DFS in patients with unresectable locally advanced esophageal cancer treated with definitive chemoradiotherapy. Treatment intensification must be considered for patients with higher MTVs.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 01/13/2018 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at https://www.ncbi.nlm.nih.gov/pubmed/24276528